Toronto Dominion Bank Sells 19,858 Shares of Novo Nordisk A/S (NYSE:NVO)

Toronto Dominion Bank trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 57.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,863 shares of the company’s stock after selling 19,858 shares during the period. Toronto Dominion Bank’s holdings in Novo Nordisk A/S were worth $1,770,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Natixis Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after buying an additional 80,070 shares during the last quarter. Zions Bancorporation N.A. raised its position in Novo Nordisk A/S by 57.0% during the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after purchasing an additional 6,726 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Novo Nordisk A/S by 14.8% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after purchasing an additional 37,346 shares during the last quarter. LRI Investments LLC increased its position in shares of Novo Nordisk A/S by 103.4% during the 3rd quarter. LRI Investments LLC now owns 12,884 shares of the company’s stock valued at $1,534,000 after purchasing an additional 6,550 shares during the last quarter. Finally, Private Wealth Partners LLC increased its position in shares of Novo Nordisk A/S by 155.1% during the 3rd quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock valued at $3,953,000 after purchasing an additional 20,188 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 1.5 %

NYSE:NVO opened at $106.95 on Monday. The firm has a market capitalization of $479.94 billion, a P/E ratio of 34.61, a P/E/G ratio of 1.43 and a beta of 0.40. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The company has a fifty day moving average of $110.59 and a 200 day moving average of $126.17. Novo Nordisk A/S has a 52 week low of $96.53 and a 52 week high of $148.15.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on NVO shares. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Friday. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $150.40.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.